» Articles » PMID: 37284893

Isolation and Characterization of a VHH Targeting the Acinetobacter Baumannii Cell Surface Protein CsuA/B

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Acinetobacter baumannii is a Gram-negative bacterial pathogen that exhibits high intrinsic resistance to antimicrobials, with treatment often requiring the use of last-resort antibiotics. Antibiotic-resistant strains have become increasingly prevalent, underscoring a need for new therapeutic interventions. The aim of this study was to use A. baumannii outer membrane vesicles as immunogens to generate single-domain antibodies (VHHs) against bacterial cell surface targets. Llama immunization with the outer membrane vesicle preparations from four A. baumannii strains (ATCC 19606, ATCC 17961, ATCC 17975, and LAC-4) elicited a strong heavy-chain IgG response, and VHHs were selected against cell surface and/or extracellular targets. For one VHH, OMV81, the target antigen was identified using a combination of gel electrophoresis, mass spectrometry, and binding studies. Using these techniques, OMV81 was shown to specifically recognize CsuA/B, a protein subunit of the Csu pilus, with an equilibrium dissociation constant of 17 nM. OMV81 specifically bound to intact A. baumannii cells, highlighting its potential use as a targeting agent. We anticipate the ability to generate antigen-specific antibodies against cell surface A. baumannii targets could provide tools for further study and treatment of this pathogen. KEY POINTS: •Llama immunization with bacterial OMV preparations for VHH generation •A. baumannii CsuA/B, a pilus subunit, identified by mass spectrometry as VHH target •High-affinity and specific VHH binding to CsuA/B and A. baumannii cells.

Citing Articles

Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.

Lei E, Azmat A, Henry K, Hussack G Appl Microbiol Biotechnol. 2024; 108(1):232.

PMID: 38396192 PMC: 10891261. DOI: 10.1007/s00253-024-13033-5.

References
1.
Alata W, Yogi A, Brunette E, Delaney C, van Faassen H, Hussack G . Targeting insulin-like growth factor-1 receptor (IGF1R) for brain delivery of biologics. FASEB J. 2022; 36(3):e22208. DOI: 10.1096/fj.202101644R. View

2.
Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, Mackenzie R . Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng Des Sel. 2008; 22(2):59-66. DOI: 10.1093/protein/gzn071. View

3.
Asif M, Alvi I, Rehman S . Insight into : pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018; 11:1249-1260. PMC: 6110297. DOI: 10.2147/IDR.S166750. View

4.
Azizi O, Shahcheraghi F, Salimizand H, Modarresi F, Shakibaie M, Mansouri S . Molecular Analysis and Expression of Gene in Biofilm-Forming Multi-Drug-Resistant . Rep Biochem Mol Biol. 2017; 5(1):62-72. PMC: 5214686. View

5.
Baral T, MacKenzie R, Arbabi Ghahroudi M . Single-domain antibodies and their utility. Curr Protoc Immunol. 2014; 103:2.17.1-2.17.57. DOI: 10.1002/0471142735.im0217s103. View